A case of stunning of lung and bone metastases of papillary thyroid cancer after a therapeutic dose (3.7 GBq) of 131I and review of the literature: Implications or sequential treatments

British Journal of Radiology

Volumn 78, Issue 929, 2005, Pages 428-432

  Leger, A F ^a   Pellan, M ^a   Dagousset, F ^a   Chevalier, A ^a   Keller, I ^a   Clerc, J ^a  

^a HÔPITAL NECKER ENFANTS MALADES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

IODINE 131; LEVOTHYROXINE; RECOMBINANT THYROTROPIN;

ADOLESCENT; ARTICLE; BONE METASTASIS; BONE SCINTISCANNING; CASE REPORT; CAUCASIAN; CELL VIABILITY; CERVICAL LYMPH NODE; COMPUTER ASSISTED TOMOGRAPHY; DISEASE COURSE; DISEASE DURATION; HUMAN; IMAGE ANALYSIS; LUNG METASTASIS; LUNG SCINTISCANNING; LYMPH NODE BIOPSY; LYMPHADENOPATHY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; RADIATION DOSE; THYROID CANCER; THYROID CELL; THYROIDECTOMY; WHOLE BODY SCINTISCANNING;

ADOLESCENT; BONE NEOPLASMS; CARCINOMA, PAPILLARY; DOSE-RESPONSE RELATIONSHIP, RADIATION; HUMANS; IODINE RADIOISOTOPES; LUNG NEOPLASMS; MAGNETIC RESONANCE IMAGING; MALE; NEOPLASM, RESIDUAL; RADIOPHARMACEUTICALS; RADIOTHERAPY DOSAGE; RECOMBINANT PROTEINS; THYROID NEOPLASMS; THYROIDECTOMY; THYROTROPIN; WHOLE-BODY COUNTING;

EID: 18844433819     PISSN: 00071285     EISSN: None     Source Type: Journal    
DOI: 10.1259/bjr/92548685     Document Type: Article

References (38)

1. Mazzaferri EL. An overview of the management of papillary and follicular thyroid carcinoma. Thyroid 1999;9:421-7.
2. Wartofsky L, Sherman SI, Gopal J, Schlumberger M, Hay ID. The use of radioactive iodine in patients with papillary and follicular thyroid cancer. J Clin Endocrinol Metab 1998;83:4195-203.
3. British Thyroid Association and Royal College of Physicians. Guidelines for the management of thyroid cancer in adults. London: Royal College of Physicians, 2002.
4. Coakley AJ, Page CJ, Croft D. Scanning dose and detection of thyroid metastases. J Nucl Med 1980;21:803-4.
5. Jeevanram RK, Shah DH, Sharma SM, Ganatra RD. Influence of initial large dose on subsequent uptake of therapeutic radioiodine in thyroid cancer patients. Int J Rad Appl Instrum B 1986;13:277-9.
6. Park HM, Perkins OW, Edmondson JW, Schnute RB, Manatunga A. Influence of diagnostic radioiodines on the uptake of ablative dose of iodine-131. Thyroid 1994;4:49-54.
7. 131I. Nucl Med Commun 1996;17:839-42.
8. Park HM, Park YH, Zhou XH. Detection of thyroid remnant/metastasis without stunning: an ongoing dilemma. Thyroid 1997;7:277-80.
9. Leger FA, Izembart M, Dagousset F, Barritault L, Baillet G, Chevalier A, et al. Decreased uptake of therapeutic doses of iodine-131 after 185-MBq iodine-131 diagnostic imaging for thyroid remnants in differentiated thyroid carcinoma. Eur J Nucl Med 1998;25:242-6.
10. Muratet JP, Daver A, Minier JF, Larra F. Influence of scanning doses of iodine-131 on subsequent first ablative treatment outcome in patients operated on for differentiated thyroid carcinoma. J Nucl Med 1998;39:1546-50.
11. Hurley JR. Management of thyroid cancer: radioiodine ablation, "stunning," and treatment of thyroglobulin-positive, (131)I scan-negative patients. Endocr Pract 2000;6: 401-6.
12. Diehl M, Grunwald F. Stunning after tracer dosimetry. J Nucl Med 2001;42:1129.
13. Yeung HW, Humm JL, Larson SM. Radioiodine uptake in thyroid remnants during therapy after tracer dosimetry. J Nucl Med 2000;41:1082-5.
14. 131I on postsurgical thyroid remnants. J Nucl Med 2000;41:2038-42.
15. McMenemin RM, Hilditch TE, Dempsey MF, Reed NS. Thyroid stunning after (131)I diagnostic whole-body scanning. J Nucl Med 2001;42:986-7.
16. 131I. Eur J Nucl Med Mol Imaging 2002; 29:1421-7.
17. 123I. Eur J Nucl Med Mol Imaging 2002;29:783-8.
18. Guiraud-Vitaux F, Feldmann G, Vadrot N, Charles-Gupta S, Durand-Schneider AM, Colas-Linhart N, et al. Early ultrastructural injuries in the thyroid of the normal rat radioinduced by diagnostic and/or therapeutic amounts of iodine-131. Cell Mol Biol 2001;47:495-502.
19. Postgard P, Himmelman J, Lindencrona U, Bhogal N, Wiberg D, Berg G, et al. Stunning of iodide transport by (131)I irradiation in cultured thyroid epithelial cells. J Nucl Med 2002;43:828-34.
20. Wu HS, Hseu HH, Lin WY, Wang SJ, Liu YC. Decreased uptake after fractionated ablative doses of iodine-131. Eur J Nucl Med Mol Imaging 2005;32:167-73.
21. Shen DH, Kloos RT, Mazzaferri EL, Jhian SM. Sodium iodide symporter in health and disease. Thyroid 2001;11: 415-25.
22. Dohan O, De la Vieja A, Paroder V, Riedel C, Artani M, Reed M, et al. The sodium/iodide symporter (NIS): characterization, regulation, and medical significance. Endocr Rev 2003;24:48-77.
23. Coakley AJ. Thyroid stunning. Eur J Nucl Med 1998;25:203-4.
24. Medvedec M. Thyroid stunning. J Nucl Med 2001;42: 1129-31.
25. Medvedec M. Seeking a radiobiological explanation for thyroid stunning. Eur J Nucl Med 2001;28:393-5.
26. Brenner W. Is thyroid stunning a real phenomenon or just fiction? J Nucl Med 2002;43:835-6.
27. Morris LF, Waxman AD, Braunstein GD. Thyroid stunning. Thyroid 2003;13:333-40.
28. 131I (i.e. it does not cause stunning) in differentiated thyroid cancer. Nucl Med Commun 1997; 18:505-12.
29. 131I. J Nucl Med 2000;41:1198-202.
30. 131I-scanned and nonscanned individuals. J Clin Endocrinol Metab 2001;86: 3507-11.
31. Karam M, Gianoukakis A, Feustel PJ, Cheema A, Postal ES, Cooper JA. Influence of diagnostic and therapeutic doses on thyroid remnant ablation rates. Nucl Med Commun 2003;24: 489-95.
32. Baatout S, Derradji H, Petitfour O, von Suchodoletz H, Mergeay M. Mécanismes de l'apoptose radio-induite. Can J Physiol Pharmacol 2002;80:629-37.
33. Kao CH. Stunned thyroid after a diagnostic dose of I-131 for a whole body scan. Clin Nucl Med 1998;23:102-4.
34. Sabri O, Zimny M, Schreckenberger M, Meyer-Oelmann A, Reinartz P, Buell U. Does thyroid stunning exist? A model with benign thyroid disease. Eur J Nucl Med 2000;27: 1591-7.
35. Modoni S, Martino G, Valle G, Perrone E, Frusciante V. How is thyroid remnant ablation affected by former 131-I diagnostic doses and/or elapsed time? Eur J Nucl Med 2000;27:1152.
36. Wolff J. Transport of iodide and other anions in the thyroid gland. Physiol Rev 1964;44:45-90.
37. 131I scintigraphy. Nucl Med Commun 2000;21:529-32.
38. Robbins RJ, Robbins AK. Clinical review 156: Recombinant human thyrotropin and thyroid cancer management. J Clin Endocrinol Metab 2003;88:1933-8.